The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 15, 2024

Filed:

May. 23, 2023
Applicants:

Universitat DE València, Valencia, ES;

Arthex Biotech S.l., Paterna, ES;

Inventors:

Rubén Artero Allepuz, Valencia, ES;

Nerea Moreno Cervera, Valencia, ES;

Irene González Martínez, Valencia, ES;

Estefanía Cerro Herreros, Valencia, ES;

Eric G. Marcusson, San Francisco, CA (US);

María Beatriz Llamusí Troisi, Paterna, ES;

Assignees:

UNIVERSITAT DE VALENCIA, Valencia, ES;

ARTHEX BIOTECH S.L., Paterna, ES;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61P 21/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61P 21/00 (2018.01); C12N 2310/141 (2013.01); C12N 2310/31 (2013.01);
Abstract

The invention provides oligonucleotide and/or oligonucleotide analogue molecules that are antagonists of a microRNA, preferably antagonists of human microRNAs hsa-miR-23b-3p and hsa-miR-218-5p, that comprise a mixture of phosphorothioate and phosphodiester linkages, and that are conjugated to at least one oleic acid molecule. Inhibiting these microRNAs allows to increase the endogenous levels of the corresponding proteins MBNL1 and/or MBNL2. The present invention further provides compositions comprising said oligonucleotides and/or oligonucleotide analogue molecules and their uses for the treatment and prevention of DM in a subject in need thereof.


Find Patent Forward Citations

Loading…